A B S T R A C T A new radioimmunoassay for secretin was used to investigate (a) serum secretin responses to intraduodenally infused HCl and glucose, (b) the metabolic half-life and the volume of distribution of exogenous secretin and (c) the effect of endogenously released secretin on insulin secretion in 25 anesthetized dogs. Portal and femoral venous blood samples were taken simultaneously before, during, and after intraduodenal infusion of HCl (21 meq/30 min) and glucose (131 ml/30 min). Control experiments were performed with intraduodenal infusion of saline.
cating biological activity of the circulating immunoreactive secretin.
The effect of intraduodenal infusion of glucose on immunoreactive secretin concentration was studied in 12 dogs. Glucose in concentrations ranging from 2.5% to 10% had no detectable influence on portal or peripheral secretin concentration. Infusion of 50% glucose caused a slight decline in secretin concentration.
The metabolic clearance rate, half-life of disappearance, and volume of distribution of exogenous secretin was studied in three dogs by the constant infusion technic. The metabolic clearance rate was 730±34 ml/ min, volume of distribution was 17.4±0.8% of body weight, and the half-life of disappearance was 2.8±0.1 min. It could be calculated that 1.38 U/kg-h' of endogenous secretin was released into the peripheral circulation during the steady state period of the HCl infusion experiments.
The data indicated that immunoreactive secretin was released rapidly after intestinal acidification, continued to be secreted throughout the duration of HCl infusion, and was promptly distributed in the extracellular compartment. Furthermore, they suggested that endogenously released secretin could stimulate insulin secretion. The HCl-mediated insulinogenic effect of immunoreactive secretin, however, was too weak to influence peripheral immunoreactive insulin, glucose, and free fatty acid concentrations.
The failure of intraduodenal glucose to stimulate secretin release suggests that secretin is not the insulin-stimulatory factor released from the gastrointestinal tract in response to glucose. sulin. However, confirmation of these results is urgently needed.
We have developed a sensitive and specific radioimmunoassay for secretin using an antiserum produced in rabbits to synthetic secretin and "SI-labeled synthetic secretin as tracer hormone (16) . This assay has allowed us to (a) characterize in portal and peripheral venous serum changes in secretin concentrations after HCI infusion in anesthetized dogs; (b) determine the metabolic clearance rate (MCR) and volume of distribution (V) of serum secretin after continuous infusion of exogenous secretin; and (c) delineate the interrelationship between intraduodenal glucose administration and secretin release. In addition, identification of the endogenous IRS response to intestinal acidification and demonstration of the bioactivity of the released secretin have permitted us to reassess the effect of endogenous secretin release on insulin secretion. The HCl infusion experiments included six test periods. After an initial control period (-10 min until 0 time), 15 ml HCl (160 mM solution in distilled water) was rapidly infused intraduodenally. This was followed by a constant infusion (4 ml/min) for 30 min with a Harvard Pump (Harvard Apparatus Co., Inc., Millis, Mass.). This was followed by a 30-min rest. Saline was infused during the 60-90 min interval and again followed by a 30-min rest.
METHODS
From 120 to 150 min a second HCl (160 mM) infusion was performed, in the same fashion as the first.
Similarly, the glucose infusion experiments were started with an initial control period, followed by a 30-min intraduodenal infusion of NaCl, a 30-min rest period, a 30-min glucose infusion, a second rest period and a final 30-min HCI infusion.
Simultaneous blood samples were obtained from the portal and femoral veins at frequent intervals before, during, and after HCl, glucose, or saline infusions. The blood was collected in ice-cold test tubes, allowed to clot, and centrifuged at 4°C. Fibrin clots, when present, were removed and the serum recentrifuged. Serum was stored at -15°C until assayed.
Pancreatic juice was collected at 15-min intervals into calibrated ice-cold conical glass tubes. Bicarbonate concentration was measured by adding 0.5 ml of pancreatic fluid to 1.0 ml of 0.1 N HCl, bringing the mixture briefly to boil, and back-titrating the residual HOl with 0.1 N NaOH to pH 7.0.
Secretin was measured by a radioimmunoassay that has recently been described (16) . Highly purified porcine secretin mixed with cystein HCl (batch 17171, GIH Research Laboratory, Karolinska Institute, Stockholm, Sweden) was used for standards. Each ampule contained 75 clinical U but the mass of secretin was not given. Secretin activity was therefore expressed in units as stated on the label. Microgram amounts of the secretin-cystein HCl mixture were weighed out on a Cahn electrobalance (Cahn Div., Ventron Instruments Corp., Paramount, Calif.), dissolved in 1/10 N HCl, and diluted with buffer to contain 0.05, 0.1, 0.25, 0.5, 1.0, and 2.0 mU/ml. According to recent investigations from this laboratory, 1 mU of this material is immunologically equivalent to 250 pg of the purest synthetic secretin preparation (17) . The sensitivity of the assay varied from 50 to 100 AU/sample (200-400 ,uU/ml of serum). Values below the calculated sensitivity were considered as zero. Coefficient of variation was 9.4% for intraassay and 17.1% for interassay reproducibility.
Serum insulin, glucose, and FFA were measured only in samples taken during the first HCI infusion and the following rest period. Insulin was determined by radioimmunoassay according to Soeldner and Slone (18 
MCR V =k (3) Statistical analysis was performed with Student's t test for small paired samples, and least square regression analysis was performed as described by Snedecor and Cochran (23) . Results are given as means±SEM.
RESULTS

Portal venous IRS after HCl and saline
First HCI infusion (Table I, Fig. 1 (Fig. 3) . The disappearance of IRS was measured after discontinuation of the infusion. As can be seen from Fig. 3 IRI, glucose, and FFA after HCI (Fig. 4) Portal venous IRI rose significantly from a preinfusion concentration of 38±8 uU/ml to a peak concentration of 62±18 AU/ml 30 min after the start of the HCl infusion (P < 0.05). This rise was caused by insulin increments of 94%, 90%, and 60% at 25, 20 440 ,AU/ml to 300 AU/ml during infusion with 50% glucose. The decrease of 140 AU/ml considerably exceeded possible interassay variation (16) . Fig. 6 shows a comparison of the effects on portal and femoral venous serum IRS concentrations of intraduodenal infusion of physiologic saline, 10% glucose, and HCl (21 meq/30 min). Again, saline and 10% glucose had no effect, whereas HCI elicited the same prompt IRS rise seen in the previous experiments (Fig. 1 ).
DISCUSSION
In this study a sustained increase in IRS concentration in response to intestinal acidification was demonstrated by direct measurement of the hormone in serum. The acid load utilized to achieve this effect (21 meq/30 min) in anesthetized dogs was greater than that used by Preshaw, Cooke, and Grossman (4) to provoke maximal pancreatic secretory response in alert dogs (8-12 meq/30 min). However, it was within the range of gastric acid output observed by Rune and Henricksen in dogs after a protein meal (24) and was therefore considered to be physiologic. The increase in pancreatic flow rate and bicarbonate concentration, which closely followed the rise in peripheral IRS concentrations, demonstrated the biological effectiveness of the measured immunoreactive secretin. The mean peak flow rate, 6.7 ml/15 min (range 4.2-8.5) was approximately one-half of the flow rate observed by Preshaw et al. in alert dogs with chronic pancreatic fistulas (4). It has long been known, however, that anesthesia depresses pancreatic exocrine secretion for reasons that are not entirely clear.
Preinfusion IRS levels were too low to be detected in portal venous serum in two and in femoral venous serum in three of the six dogs. Mean IRS concentrations in the remaining animals were 470 /uU/ml in portal and 440 uU/ml in femoral venous serum. IRS concentration was about 10-30% higher in portal than femoral venous serum during periods of nonstimulation, i.e., the preinfusion and saline infusion periods. This suggests that under the conditions of these experiments there was continuous basal secretion of secretin into the portal circulation. The observed base-line pancreatic exocrine secretion supports this conclusion.
Intestinal acidification resulted in a rapid increase in IRS concentrations in both portal and femoral venous blood of all animals. The portal venous IRS increase was evident at the first blood sampling, collected 2.5 min after the start of the HCl infusion. It became statistically significant at 5 min and peaked at 10 min. The femoral venous IRS response was slightly delayed. IRS remained elevated and rather constant throughout the acid infusion and declined promptly when the infusion of HCl was discontinued.
Wang and Grossman investigated the effect of intraduodenal NaCl instillation on pancreatic excretory volume in dogs and saw no significant changes (25) . Our observation of an insignificant portal IRS rise is in agreement with their findings. The possibility that the absence of IRS changes during saline infusion might have been due to unresponsiveness of the intestinal mucosa could be excluded by the results of the second HCl infusion. This HC1 stimulation resulted in IRS increases quantitatively comparable to the increments seen 120 min earlier, during the first HCl infusion.
In the past, attempts have been made to determine the disappearance rate for secretin by indirect means. Lehnert, Stahlheber, and Forell (26) determined the change in pancreatic exocrine secretion after secretin injection in dogs. They observed a 50% decline in secretory activity in 3.2 min. Lagerlof, Ek, and Nyberg (27) , however, using similar indirect methodology, arrived at a ti of 18 min in human subjects. In this study the disappearance rate of secretin was determined by direct measurement of IRS by the continuous infusion technic. Mean ti of disappearance from peripheral venous serum was found to be 2.8 min. This value is similar to recently reported disappearance rates of the gastrin heptadecapeptide (28) (29) . The calculated V averaged 17.4% of the body weight. This suggests that secretin is distributed promptly throughout the extracellular compartment (30) .
In this study, the release of endogenous secretin into the peripheral circulation during the second half of the HCl infusion (when IRS concentrations had reached a steady state) was estimated to be 1. 38 (31) . The results of our study are in good agreement with the estimate of Meyer et al., particularly when considering the larger HCl load used in our study, which -probablv resulted in acidification of a longer part of the intestine and consequently a greater secretin release (31) . Furthermore, it would appear that the similarity of the results observed in alert (Meyer et al.) and anesthetized dogs (our study) makes it unlikely that the depressed pancreatic exocrine response in anesthetized animals is caused by inhibition of secretin release from the intestinal mucosa.
Mean measurable femoral venous IRS concentration was 440 AU/ml in the three unstimulated dogs. This concentration is considerably lower than the mean level of 1,870 AU/ml found in fasting human subjects (16) .
The reason for this difference is presently unknown but several possibilities have to be considered. First, it might simply reflect a species difference. Second, the higher IRS levels in overnight-fasted humans might not represent true basal IRS conditions. Third, it is important to realize that porcine secretin was used as tracer and reference standard in the measurements of both human and dog secretin levels. The possibility that human secretin has greater immunoreactivity than dog secretin in a porcine system cannot be excluded. For instance, it is possible that human serum contains several species of secretin with different molecular sizes and different immunological reactivity with certain antisera, as has been demonstrated recently for parathyroid hormone (32) . Lastly, it has been found that greater than usual tracer-degrading activity was responsible for spuriously high IRS concentrations in some human sera (33) . Quantitatively, however, the betacytotrophic effect of physiologic amounts of secretin appears to be rather weak. Doubling of the femoral venous IRS concentration resulted in a less than twofold augmentation of portal venous IRI concentration. In contrast, doubling of the glucose concentration has been shown to increase portal venous IRI concentration tenfold (34) . The weakness of the insulin response to endogenous secretin is further underlined by the fact that it was demonstrable in only three of the six dogs and that the changes in portal venous insulin levels were not reflected in peripheral venous insulin changes. Moreover, peripheral FFA levels, a sensitive indicator of peripheral insulin action, did not change. Nevertheless, hepatic metabolism has been shown to be exquisitely sensitive to minute amounts of insulin (35) . Therefore, it is possible that the weak insulinogenic effect of endogenous IRS may serve to prime the liver in preparation for postprandial fuel metabolism. However, other factors, such as cholecystokinin, gut glucagon, or perhaps the newly discovered gastric inhibitory peptide (36), which were not measured, also could conceivably have contributed to the HCl-mediated insulin increase.
'Boden, G. Unpublished observations. (38) . This suggests the possibility that the decline in IRS concentration seen in the dogs receiving 50% glucose intraduodenally may have been caused by a rise in portal blood flow rather than a decrease in secretin release. By the same token, it cannot completely be ruled out that in the experiments where 10% glucose was infused, a small increase in secretin release might have been obscured by a concomitant rise in portal blood flow. At any rate, the lack of changes in peripheral venous IRS concentration excludes the possibility of major alterations in secretin release. Therefore, it appears unlikely that secretin represents the as yet unidentified insulin stimulatory factor released from the gastrointestinal tract in response to oral glucose. Kraegen, Chisholm, Young, and Lazarus have recently proposed that secretin may act by potentiating the glycemic effect on insulin release (39) . However, the conditio sine qua non for this concept also would be a glucose-stimulated IRS release. This could not be demonstrated in this study.
